Tracking rare single donor and recipient immune and leukemia cells after allogeneic hematopoietic cell transplantation using mitochondrial DNA mutations

2024-9-5

Highlighted research articles

2024-9-3

Repurposing NAMPT inhibitors for germinal center B-cell-like diffuse large B-cell lymphoma

2024-8-5

Oncogenic Enhancers in Leukemia

2024-8-2

A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas

2024-7-31

Highlighted research articles

2024-7-1

CAR T-cell Resistance to Oncogenic Transformation

2024-6-21

Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia

2024-6-21

Abstract PO-012: Gain-of-function small molecules to reprogram oncogenic transcription in lymphoma

2024-6-19

Abstract PO-007: A phase 1 study of romidepsin, azacitidine, dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignancies

2024-6-19

Abstract PO-019: Ubiquitin E3 ligase OSTM1 regulates the cAMP/PKA/CREB pathway and suppresses B-cell malignancies

2024-6-19

Abstract PR03: Immunosurveillance of precancerous germinal center B cells

2024-6-19

Abstract PO-020: ZBTB24 is a novel tumor suppressor and cooperates with CDKN2A to suppress B-cell lymphomagenesis

2024-6-19

Abstract PO-032: A novel strategy to overcome resistance of diffuse large B-cell lymphoma to venetoclax

2024-6-19

Abstract PO-030: Single cell spatial analysis of large B cell lymphoma identifies biomarkers correlated with genetic subtypes and clincal outcomes

2024-6-19

Abstract PO-033: Unveiling the complexity of HIV-associated plasmablastic lymphoma: A case report of anal cavity presentation with unconventional immunohistochemical profile

2024-6-19

Abstract PO-003: Peripheral blood and tumor tissue biomarkers associated with epcoritamab response in patients with relapsed or refractory diffuse large B-cell lymphoma: Data from the dose-expansion cohort of the phase 1/2 EPCORE NHL-1 trial (NCT03625037)

2024-6-19

Abstract PO-022: Distinct intratumoral microbiome signatures enrichment in patients with different Anaplaplastic Large Cell Lymphoma (ALCL) subtypes

2024-6-19

Abstract PO-023: CD70 deregulation in follicular lymphoma at diagnosis is associated with relapse and opens new avenues for dual CD19-CD70 CAR-T therapy

2024-6-19

Abstract PR05: Single-cell transcriptomics reveals shared and subtype-specific vulnerabilities of the tumor-microenvironment ecosystems in peripheral T-cell lymphomas

2024-6-19

Abstract PO-028: A high-throughput bone marrow 3D co-culture system to develop resistance to targeted agents in marginal zone lymphoma

2024-6-19

Abstract PO-036: Targeting the CBM signalosome with a MALT1 scaffolding inhibitor for treatment of non-Hodgkin lymphomas

2024-6-19

Abstract PO-016: Test-the-test: Clinical utility of comprehensive whole exome sequencing (WES) and RNA-seq for lymphoma patients

2024-6-19

Abstract PO-008: Phase I/II study of VIP152 (enitociclib), venetoclax, and prednisone (VVIP) in relapsed/refractory (R/R) lymphoid malignancies

2024-6-19

Abstract PO-006: ABBV-319: A CD19–targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies

2024-6-19

Abstract PO-035: Genome-wide CRISPR knockout screen identifies sialylation as a tumor suppressive mechanism in B-cell malignancies

2024-6-19

Abstract PO-005: Mechanistic models of cancer heterogeneity explain and predict clinical outcomes of Large B-Cell Lymphoma (LBCL) treatment

2024-6-19

Abstract PO-018: Commensal bacteria are required for chronic inflammation and B lymphoma development in myeloid cell-specific TRAF3-deficient mice

2024-6-19

Abstract PR04: Characterization of an essential <i>MYC</i> enhancer targeted by focal genomic alterations in diffuse large B-cell lymphoma

2024-6-19

Abstract PO-009: AC676 a BTK Chimeric Degrader: Phase 1 study in patients with B-cell Malignancies

2024-6-19

Abstract PR06: Comprehensive characterization of the non-tumor microenvironment of relapsed/refractory large B-cell lymphoma identifies patients with greatest benefit from CD19 CAR T-cell therapy

2024-6-19

Abstract PR07: <i>SETD1B</i> mutations confer apoptosis resistance and BCL2 independence in B-cell lymphoma

2024-6-19

Abstract PO-037: Machine learning-enabled transomics identifies three therapeutic targets for MYC-driven diffuse large B cell lymphoma

2024-6-19

Abstract PO-025: Identifying tissue-specific drivers of immune evasion in Mantle Cell Lymphoma at single cell level

2024-6-19

Abstract PO-015: The RNA helicase DDX21 cooperates with ETS1 and FLI1 in cell cycle regulation, immune evasion and small nucleolar RNA processing to sustain the survival of DLBCL cells

2024-6-19

Abstract PO-021: Modeling marginal zone lymphomagenesis

2024-6-19

Abstract PO-038: Unbiased discovery of novel antibody therapies that stimulate macrophage-mediated destruction of B-cell lymphoma

2024-6-19

Abstract PR01: EZH2 inhibitors improve CAR-T therapy by enhancing lymphoma B cell immunogenicity and CAR-T cell functions

2024-6-19

Abstract PO-002: Intrinsically disordered regions -induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers

2024-6-19

Abstract PO-031: Systematic discovery of chemotherapy response biomarkers in Peripheral T Cell Lymphomas

2024-6-19

Abstract PO-010: Trial in Progress: Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma

2024-6-19

Abstract PO-034: Targeting metabolic plasticity and flexibility via SIRT3 inhibition to restrain nucleotides availability in DLBCLs

2024-6-19

Abstract PO-001: GPR65-low tumor clones reprogram macrophage via VEGF signaling and confer antigen-independent CAR-T resistance

2024-6-19

Abstract PO-040: Mechanisms of action of immune checkpoint blockade therapy in EZH2/Bcl2-mutant B-cell lymphomas

2024-6-19

Abstract PR02: Aging-associated molecular and cellular alterations determine the biology and clinical characteristics of DLBCL in elderly patients

2024-6-19

Abstract PO-013: Combined epigenetic therapy to induce latency II/III antigen expression in latency I EBV+ lymphoma

2024-6-19

Mis-splicing of mitotic regulators sensitizes SF3B1-mutated human HSCs to CHK1 inhibition

2024-6-10

Long-term Remissions Following CD20-directed Chimeric Antigen Receptor Adoptive T cell Therapy

2024-5-10

Genotoxicity associated with retroviral CAR transduction of ATM-deficient T cells

2024-5-9

The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy

2024-5-7